| Autor: |
Holdener EE, Hansen HH, Høst H, Bruntsch U, Cavalli F, Renard J, Pinedo HM, Rozencweig M |
| Jazyk: |
angličtina |
| Zdroj: |
Investigational new drugs [Invest New Drugs] 1985; Vol. 3 (1), pp. 63-6. |
| DOI: |
10.1007/BF00176826 |
| Abstrakt: |
Epirubicin, a stereoisomer of doxorubicin with suggested lower potential for cardiotoxicity in experimental animal tumor systems, was studied in a disease-oriented phase II trial in patients with advanced colorectal cancer. The drug was given as a direct iv injection of 90 mg/m2 q 3 weeks. No objective response was observed in 52 evaluable patients with colon (n = 34) and rectal (n = 18) carcinoma. Fourteen patients (27%) had stable disease for a median of four treatment courses. Leukopenia (88%), nausea and vomiting (71%) and alopecia (54%) were the most common toxic effects. We conclude that epirubicin at the present dose and schedule is an ineffective agent in patients with metastatic colorectal cancer. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink